Lemtrada

Type: Product
Name: Lemtrada
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

3 Reasons Sanofi's Stock Could Rise

After a rocky second quarter, biopharma stocks have rallied in a big way heading toward the end of the year. Gilead Sciences, for example, has shot up 41.5% year to date, with most of this upward movement coming in recent weeks. Sanofi's anemic gains, ... [Published Motley Fool - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 27 2014 - 1 reports

Regulatory CD8 positive T cells controlling autoimmunity

Ping Y, Bamford R, Waldmann TA. IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells. Eur J Immunol. 2014 doi: 10.1002/eji.201444675. [Epub ahead of print]Interleukin-15 ... [Published Multiple Sclerosis Research - Aug 27 2014]
First reported Aug 24 2014 - Updated Aug 24 2014 - 1 reports

Politics: drug pricing

Do Pharma CEOs' deserve their large bonuses? #MSBlog #MSResearch "Do MS DMTs justify their current premium? A large number of MS drugs are repurposed and hence their risk of failure has been low. Despite this the costs remain high.""Re-purposed licensed ... [Published Multiple Sclerosis Research - Aug 24 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

FDA Red Tape Blocks Effective Treatments

A dozen sunscreens sold abroad are more effective than those available here, but U.S. regulators have yet to OK them. A promising new MS drug, Lemtrada, has been in use for years in Europe yet American officials have rejected it. And it can take 15 years ... [Published NewsMax.com - Aug 21 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

MSology at ACTRIMS-ECTRIMS – BOSTON 2014

The largest event on MS research will be the joint meeting of ACTRIMS-ECTRIMS, which will be held from September 10-13. MSology will be attending this year’s meeting in Boston. A lot of new information will be presented, so you can help us pick the ... [Published MSology - Aug 14 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

Sanofi Appears To Be In The Early Stages Of An Earnings Rebound

Summary Patent expiries restrained earnings and share-price gains the last several years. Sales erosion stemming from generic copies are now mostly in the rear-view mirror. Investors seem a little late in recognizing the unfolding of an earnings recovery. ... [Published Seeking Alpha - Aug 11 2014]
First reported Aug 10 2014 - Updated Aug 10 2014 - 1 reports

Anyone here having trouble paying for MS drugs? I have possible solution....

I’m new to this forum and decided to post this incase I might be able to help others. I have MS (for 13 yrs now) but am doing very well on LDN and the Dr Roy Swank diet, thank goodness!!…but a close friend of mine who also has MS was having great difficulties ... [Published HealthBoards - Aug 10 2014]
Entities: Lemtrada, Diet
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

MS market set to grow 4% annually

The multiple sclerosis (MS) market across the world's biggest pharma territories is set to grow by 4% annually over the next decade, according to analysts.Decision Resources Group says revenues in the therapy area will steady growth between now and 2023 ... [Published PMLive - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

New results for two novel therapies

Promising new results have now been published for two monoclonal antibody (MAb) drugs in development that may provide additional options over the next few years. MAbs are biological agents that target highly specific targets. MAbs currently used in MS ... [Published MSology - Aug 07 2014]
First reported May 30 2014 - Updated May 31 2014 - 4 reports

US FDA accepts Genzyme's Lemtrada resubmission for review

The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.  A ... [Published PharmaBiz - May 31 2014]
First reported May 28 2014 - Updated May 29 2014 - 2 reports

NICE recommends Lemtrada® (alemtuzumab) for use on the NHS for the treatment of active relapsing remitting multiple sclerosis

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending that Lemtrada should be reimbursed on the NHS, as an option for treating adults with active RRMS... ... [Published MS News - May 29 2014]
Entities: Lemtrada, Alemtuzumab, NHS
First reported May 28 2014 - Updated May 28 2014 - 2 reports

NICE recommends Genzyme’s Lemtrada for reimbursement on NHS

The UK's National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Genzyme's Lemtrada (alemtuzumab) to be reimbursed on the NHS, for treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with ... [Published PBR - News - May 28 2014]
Entities: Lemtrada, Genzyme Corp, NHS

Quotes

"It was reassuring though that the vast majority of you support a trial to test Alemtuzumab in SPMS and  that you don't think the risks of alemtuzumab outway the undefined benefits in this population, despite the Cambridge group suggesting the drug may not be effective in SPMS. I hope Genzyme staff take note of this."
"Please read my previous post on the politics of high drug pricing ." Barlas S Are specialty drug prices destroying insurers and hurting consumers?: a number of efforts are under way to reduce price pressure...
"Our solid second quarter performance reflects consistent execution of our growth strategy and allows us to slightly adjust upwards our 2014 financial guidance. This quarter, growth platforms represented more than 75% of our sales. Based on the solid momentum in our late stage pipeline, we are actively preparing for a wave of new product launches that will further redefine Sanofi as a biopharmaceutical leader."
than 2013 at CER(1), barring major unforeseen adverse Sanofi Chief Executive Officer, Christopher A Viehbacher "Our solid second quarter performance reflects consistent"

More Content

All (88) | News (27) | Reports (0) | Blogs (47) | Audio/Video (0) | Fact Sheets (0) | Press Releases (13)
sort by: Date | Relevance
Preliminary alemtuzumab survey results [Published Multiple Sclerosis Research - Aug 31 2014]
OpportunityAnalyzer: Graft-Versus-Host Disease ... [Published MarketResearch.com - Aug 30 2014]
GVHD Industry (Life sciences) Insights & Analys... [Published MyNewsDesk - Aug 29 2014]
3 Reasons Sanofi's Stock Could Rise [Published Motley Fool - Aug 28 2014]
Regulatory CD8 positive T cells controlling aut... [Published Multiple Sclerosis Research - Aug 27 2014]
OpportunityAnalyzer: Graft-Versus-Host Disease ... [Published PredictWallStreet - Aug 25 2014]
OpportunityAnalyzer: Graft-Versus-Host Disease ... [Published Global Information Inc - Aug 25 2014]
Politics: drug pricing [Published Multiple Sclerosis Research - Aug 24 2014]
GVHD Market (Graft-Versus-Host Disease) Growing... [Published EMAILWIRE.com - Aug 22 2014]
FDA Red Tape Blocks Effective Treatments [Published NewsMax.com - Aug 21 2014]
New drugs to boost graft-versus-host disease tr... [Published Pharma Letter - Aug 15 2014]
New Drugs to Boost Graft-Versus-Host Disease Tr... [Published PharmaAsia - Aug 15 2014]
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
Sanofi Appears To Be In The Early Stages Of An ... [Published Seeking Alpha - Aug 11 2014]
Anyone here having trouble paying for MS drugs?... [Published HealthBoards - Aug 10 2014]
MS market to reach $20 billion in 2023 boosted ... [Published Pharma Letter - Aug 08 2014]
MS market set to grow 4% annually [Published PMLive - Aug 08 2014]
New results for two novel therapies [Published MSology - Aug 07 2014]
Sanofi Beats on Q2 Earnings, View Up on Strong ... [Published Zacks.com - Aug 01 2014]
Stocks To Watch: Sanofi SA Rights [Published Seeking Alpha - Aug 01 2014]
Sanofi Investing €700 Million Ahead Of Launches [Published BioPortfolio - Jul 31 2014]
Multiple sclerosis treatment landscape has unde... [Published Live-PR.com - Jul 31 2014]
SANOFI: Solid sales and Business EPS(1) growth ... [Published Virtual Strategy Magazine - Jul 31 2014]
SANOFI: Solid sales and Business EPS(1) growth ... [Published Scottrade - Jul 31 2014]
SANOFI: Solid sales and Business EPS(1) growth ... [Published Scottrade - Jul 31 2014]
New MS drug Lemtrada approved for use in Scotland [Published MS News - Jul 07 2014]
Argentina approves Genzyme’s Lemtrada for multi... [Published Pharmaceutical Technology - Jul 02 2014]
Genzyme gets approval for Lemtrada in Argentina... [Published PBR - News - Jul 02 2014]
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Genzyme Press Release - Jun 30 2014]
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Business Wire Health News - Jun 30 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Preliminary alemtuzumab survey results [Published Multiple Sclerosis Research - Aug 31 2014]
When the results of a survey change the way you see the world; having progressive MS is like having a different disease. #MSBlog #MSResearch "Last week I did a ClinicSpeak post on ' when to say no to alemtuzumab ' and linked it to a survey. The preliminary ...
Regulatory CD8 positive T cells controlling aut... [Published Multiple Sclerosis Research - Aug 27 2014]
Ping Y, Bamford R, Waldmann TA. IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells. Eur J Immunol. 2014 doi: 10.1002/eji.201444675. [Epub ahead of print]Interleukin-15 ...
Politics: drug pricing [Published Multiple Sclerosis Research - Aug 24 2014]
Do Pharma CEOs' deserve their large bonuses? #MSBlog #MSResearch "Do MS DMTs justify their current premium? A large number of MS drugs are repurposed and hence their risk of failure has been low. Despite this the costs remain high.""Re-purposed licensed ...
MSology at ACTRIMS-ECTRIMS – BOSTON 2014 [Published MSology - Aug 14 2014]
The largest event on MS research will be the joint meeting of ACTRIMS-ECTRIMS, which will be held from September 10-13. MSology will be attending this year’s meeting in Boston. A lot of new information will be presented, so you can help us pick the ...
Anyone here having trouble paying for MS drugs?... [Published HealthBoards - Aug 10 2014]
I’m new to this forum and decided to post this incase I might be able to help others. I have MS (for 13 yrs now) but am doing very well on LDN and the Dr Roy Swank diet, thank goodness!!…but a close friend of mine who also has MS was having great difficulties ...
1 2 3 4 5 6 7 8 9 10

Press Releases

sort by: Date | Relevance
Genzyme’s Lemtrada Approved in Argentina for Tr... [Published Genzyme Press Release - Jun 30 2014]
Genzyme’s Lemtrada Resubmission Accepted for Re... [Published Genzyme Press Release - May 30 2014]
Genzyme’s Lemtrada Resubmission Accepted for Re... [Published Sanofi.com - Last press releases - May 30 2014]
Genzyme’s Lemtrada Recommended for Reimbursemen... [Published Genzyme Press Release - May 28 2014]
Sanofi: Slowing of Brain Atrophy and Reductions... [Published GlobeNewswire: Advertising News - Apr 30 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.